The complete genome sequence of Chromobacterium violaceum reveals remarkable and exploitable bacterial adaptability

Chromobacterium violaceum is one of millions of species of free-living microorganisms that populate the soil and water in the extant areas of tropical biodiversity around the world. Its complete genome sequence reveals (i) extensive alternative pathways for energy generation, (ii) ≈500 ORFs for transport-related proteins, (iii) complex and extensive systems for stress adaptation and motility, and (iv) wide-spread utilization of quorum sensing for control of inducible systems, all of which underpin the versatility and adaptability of the organism. The genome also contains extensive but incomplete arrays of ORFs coding for proteins associated with mammalian pathogenicity, possibly involved in the occasional but often fatal cases of human C. violaceum infection. There is, in addition, a series of previously unknown but important enzymes and secondary metabolites including paraquat-inducible proteins, drug and heavy-metal-resistance proteins, multiple chitinases, and proteins for the detoxification of xenobiotics that may have biotechnological applications

Influência do alimento na produção e qualidade do leite de cabra Influence of feed on the production on quality of goat milk

O leite de cabra é considerado um dos alimentos mais completos por apresentar vários elementos importantes para a nutrição humana, constituído de proteínas de alto valor biológico e ácidos graxos essenciais, além de seu conteúdo mineral e vitamínico. Esta revisão tem como objetivo avaliar as variações referentes à composição química e propriedades físicoquímicas do leite, que ocorrem em função de alguns fatores, tais como: climáticos, raça, indivíduo, estágio de lactação e alimentação. O manejo alimentar tem sido considerado um fator preponderante na manipulação dos componentes do leite. Há um entendimento dominante que a gordura é o componente do leite que mais sofre influência dos alimentos. O uso de técnicas biológicas moleculares poderá contribuir para o entendimento do mecanismo de utilização do alimento no rúmen, estabelecendo um novo cenário para a microbiologia ruminal, que pode ser diferente do que tem sido estudado até o momento.<br>Goat milk is considered one of the most complete foods, since it holds several elements which are important for human nutrition, and necessary for the constitution of tissues and blood. This revision aims to assess the variations of the chemical composition and physical-chemical properties of the milk which occur due to some factors, such as: climate, breed, the individual, lactation stage and food. Feed management has been considered a key factor in the manipulation of milk components. There is a general understanding that among the components of the milk fat is the most influenced by food. The use of molecular biological techniques might contribute to the understanding of the mechanism of utilization of food in rumen, establishing a new possibility for ruminal microbiology, which can be different from what has been studied so far

Vorapaxar in the secondary prevention of atherothrombotic events

Item does not contain fulltextBACKGROUND: Thrombin potently activates platelets through the protease-activated receptor PAR-1. Vorapaxar is a novel antiplatelet agent that selectively inhibits the cellular actions of thrombin through antagonism of PAR-1. METHODS: We randomly assigned 26,449 patients who had a history of myocardial infarction, ischemic stroke, or peripheral arterial disease to receive vorapaxar (2.5 mg daily) or matching placebo and followed them for a median of 30 months. The primary efficacy end point was the composite of death from cardiovascular causes, myocardial infarction, or stroke. After 2 years, the data and safety monitoring board recommended discontinuation of the study treatment in patients with a history of stroke owing to the risk of intracranial hemorrhage. RESULTS: At 3 years, the primary end point had occurred in 1028 patients (9.3%) in the vorapaxar group and in 1176 patients (10.5%) in the placebo group (hazard ratio for the vorapaxar group, 0.87; 95% confidence interval [CI], 0.80 to 0.94; P<0.001). Cardiovascular death, myocardial infarction, stroke, or recurrent ischemia leading to revascularization occurred in 1259 patients (11.2%) in the vorapaxar group and 1417 patients (12.4%) in the placebo group (hazard ratio, 0.88; 95% CI, 0.82 to 0.95; P=0.001). Moderate or severe bleeding occurred in 4.2% of patients who received vorapaxar and 2.5% of those who received placebo (hazard ratio, 1.66; 95% CI, 1.43 to 1.93; P<0.001). There was an increase in the rate of intracranial hemorrhage in the vorapaxar group (1.0%, vs. 0.5% in the placebo group; P<0.001). CONCLUSIONS: Inhibition of PAR-1 with vorapaxar reduced the risk of cardiovascular death or ischemic events in patients with stable atherosclerosis who were receiving standard therapy. However, it increased the risk of moderate or severe bleeding, including intracranial hemorrhage. (Funded by Merck; TRA 2P-TIMI 50 ClinicalTrials.gov number, NCT00526474.)